Cytokines in cancer drug resistance: Cues to new therapeutic strategies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 2, 2016, Pages 255-265

  Jones, Valerie Sloane ^a   Huang, Ren Yu ^a   Chen, Li Pai ^b   Chen, Zhe Sheng ^c   Fu, Liwu ^d   Huang, Ruo Pan ^a,e  

^a RayBiotech   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c ST JOHN'S UNIVERSITY   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e South China Biochip Research Center   (China)

Author keywords

Antibody array; Cancer drug resistance; Cytokine; Multiplex immunoassay; Stromal cells; Tumor microenvironment

Indexed keywords

ADRENOMEDULLIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BORTEZOMIB; CYTOKINE; DOXORUBICIN; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GEMCITABINE; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MITOMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NILOTINIB; PACLITAXEL; RANTES; SCATTER FACTOR; STAT3 PROTEIN; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELLULAR SECRETION; CHRONIC MYELOID LEUKEMIA; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; KIDNEY METASTASIS; LYMPHOCYTE DIFFERENTIATION; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MESENCHYME CELL; OVERALL SURVIVAL; PANCREAS CANCER CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; STROMA CELL; T LYMPHOCYTE; DRUG RESISTANCE; IMMUNOLOGY; NEOPLASMS; PHYSIOLOGY;

CYTOKINES; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; STROMAL CELLS;

EID: 84962300554     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.03.005     Document Type: Review

References (114)

1. Frei E., et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965, 26(5):642-656.
2. Frei E., Freireich E.J. Progress and perspectives in the chemotherapy of acute leukemia. Adv. Chemother. 1965, 2:269-298.
3. Haber D.A., Gray N.S., Baselga J. The evolving war on cancer. Cell 2011, 145(1):19-24.
4. Zahreddine H., Borden K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol. 2013, 4:28.
5. Holohan C., et al. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13(10):714-726.
6. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
7. Bai J., et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005, 65(6):2344-2352.
8. Wang G., et al. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One 2012, 7(12).
9. Niero E.L., et al. The multiple facets of drug resistance: one history, different approaches. J. Exp. Clin. Cancer Res. 2014, 33:37.
10. Ho E.A., Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr. Cancer Drug Targets 2006, 6(4):295-311.
11. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352(16):1685-1695.
12. Moser B., et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004, 25(2):75-84.
13. Belperio J.A., et al. CXC chemokines in angiogenesis. J. Leukoc. Biol. 2000, 68(1):1-8.
14. Janes K.A., et al. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005, 310(5754):1646-1653.
15. de Visser K.E., Jonkers J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr. Pharm. Des. 2009, 15(16):1844-1853.
16. McMillin D.W., Negri J.M., Mitsiades C.S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 2013, 12(3):217-228.
17. Wilson J.J., et al. Antibody arrays in biomarker discovery. Adv. Clin. Chem. 2015, 69:255-324.
18. Burkholder B., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim. Biophys. Acta 2014, 1845(2):182-201.
19. Ruo-Pan Huang B.B., Jones Valerie Sloane, Jiang Wei-Dong, Mao Ying-Qing, Chen Qiao-Lin, Shi Zhi Cytokine antibody arrays in biomarker discovery and validation. Curr. Proteomics 2012, 9(1):55-70.
20. Wilson J.J., et al. Antibody Arrays in Biomarker Discovery 2015, Adv Clin Chem.
21. Goel H.L., Mercurio A.M. VEGF targets the tumour cell. Nat. Rev. Cancer 2013, 13(12):871-882.
22. Waldner M.J., Neurath M.F. Targeting the VEGF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16(1):5-13.
23. Etscheid M., et al. Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur. J. Cell Biol. 2004, 82(12):597-604.
24. Xin X., et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol. 2001, 158(3):1111-1120.
25. Seghezzi G., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 1998, 141(7):1659-1673.
26. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 1992, 59:115-165.
27. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10(6):415-424.
28. Morrison C.D., Parvani J.G., Schiemann W.P. The relevance of the TGF-beta Paradox to EMT-MET programs. Cancer Lett. 2013, 341(1):30-40.
29. Shay G., Lynch C.C., Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015, 44-46:200-206.
30. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65(23):10794-10800.
31. Dankbar B., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95(8):2630-2636.
32. Ravoet C., et al. Tumour stimulating effects of recombinant human interleukin-6. Lancet 1994, 344(8936):1576-1577.
33. Salgado R., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 2003, 103(5):642-646.
34. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999, 67(1):12-18.
35. Huang S., et al. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol. Ther. 2000, 6(1):9-17.
36. Xu L., Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol. Res. 2000, 12(2):97-106.
37. Strieter R.M., et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 2006, 42(6):768-778.
38. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 2006, 25(3):357-371.
39. Azenshtein E., et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002, 62(4):1093-1102.
40. Salcedo R., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96(1):34-40.
41. Mannino M.H., et al. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015, 367(2):103-107.
42. Benoy I.H., et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 2004, 10(21):7157-7162.
43. Berek J.S., et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 1991, 164(4):1038-1042. discussion 1042-3.
44. Schneider G.P., et al. The diverse role of chemokines in tumor progression: prospects for intervention (Review). Int. J. Mol. Med. 2001, 8(3):235-244.
45. García-Carrasco M., et al. P-glycoprotein in autoimmune rheumatic diseases. Autoimmun. Rev. 2015, 14(7):594-600.
46. Breier A., et al. New insight into p-glycoprotein as a drug target. Anti Cancer Agents Med. Chem. 2013, 13(1):159-170.
47. Sui H., Fan Z.Z., Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J. Int. Med. Res. 2012, 40(2):426-435.
48. Knüpfer H., Preiß R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 2007, 102(2):129-135.
49. Zhang G., Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999, 19(2):1427-1432.
50. Conze D., et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001, 61(24):8851-8858.
51. van Gameren M., et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994, 84(5):1434.
52. Cavarretta I.T., et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007, 26(20):2822-2832.
53. Liu C., et al. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 2014, 74(2):201-209.
54. Shi Z., et al. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res. Treat. 2012, 135(3):737-747.
55. He W., et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097. Mol. Oncol. 2011, 5(3):292-301.
56. Nakanishi C., Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5(4):297-309.
57. Li F., Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 2010, 1805(2):167-180.
58. Chaturvedi M., et al. NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011, 30(14):1615-1630.
59. Vlahopoulos S.A., et al. Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment. Cytokine Growth Factor Rev. 2015, 26(4):389-403.
60. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-[kappa] B as the matchmaker. Nat. Immunol. 2011, 12(8):715-723.
61. DiDonato J.A., Mercurio F., Karin M. NF-κB and the link between inflammation and cancer. Immunol. Rev. 2012, 246(1):379-400.
62. Hideshima T., et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood 2009, 114(5):1046-1052.
63. Li C., et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradation. J. Biol. Chem. 2010, 285(21):16096-16104.
64. Singha B., et al. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J. Biol. Chem. 2014, 289(5):2687-2700.
65. Haga A., et al. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int. J. Cancer 2003, 107(5):707-714.
66. Abasolo I., Montuenga L.M., Calvo A. Adrenomedullin prevents apoptosis in prostate cancer cells. Regul. Pept. 2006, 133(1-3):115-122.
67. Abasolo I., et al. Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP-independent autocrine mechanism. Biochem. Biophys. Res. Commun. 2004, 322(3):878-886.
68. Stassi G., et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 63(20):6784-6790.
69. Lee H.J., et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26(2):207-221.
70. Yi E.H., et al. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells. Mol. Cancer Res. 2013, 11(1):31-42.
71. Obenauf A.C., et al. Therapy-induced Tumour Secretomes Promote Resistance and Tumour Progression 2015, Nature.
72. Yano S., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68(22):9479-9487.
73. Turke A.B., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17(1):77-88.
74. Lupu R., Dickson R.B., Lippman M.E. The role of erbB-2 and its ligands in growth control of malignant breast epithelium. J. Steroid Biochem. Mol. Biol. 1992, 43(1-3):229-236.
75. Graus-Porta D., et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16(7):1647-1655.
76. Kim J.W., et al. Amphiregulin Confers Trastuzumab Resistance Via AKT and ERK Activation in HER2-positive Breast Cancer 2015, J Cancer Res Clin Oncol.
77. Turley S.J., Cremasco V., Astarita J.L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 2015, 15(11):669-682.
78. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19(11):1423-1437.
79. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
80. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432(7015):332-337.
81. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
82. Abramsson A., Lindblom P., Betsholtz C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 2003, 112(8):1142-1151.
83. Straussman R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487(7408):500-504.
84. Apte M.V., et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004, 29(3):179-187.
85. Huanwen W., et al. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol. Cancer 2009, 8:125.
86. Guan J., et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett. 2014, 345(1):132-139.
87. Bertran E., et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 2013, 58(6):2032-2044.
88. Conley-LaComb M.K., et al. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol. Cancer 2013, 12(1):85.
89. Choi Y.H., et al. CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells. Mol. Cancer Res. 2014, 12(1):38-47.
90. Lee B.C., et al. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res. 2004, 2(6):327-338.
91. Zhang H., et al. Paracrine SDF-1alpha Signaling Mediates the Effects of PSCs on GEM Chemoresistance Through an IL-6 Autocrine Loop in Pancreatic Cancer Cells 2014, Oncotarget.
92. Manier S., et al. Bone marrow microenvironment in multiple myeloma progression. J. Biomed. Biotechnol. 2012, 2012:157496.
93. Li X., et al. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway. Arch. Toxicol. 2015, 89(1):121-136.
94. Traer E., et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012, 26(5):1140-1143.
95. Gallipoli P., et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 2014, 124(9):1492-1501.
96. Tabe Y., Konopleva M. Advances in understanding the leukaemia microenvironment. Br. J. Haematol. 2014, 164(6):767-778.
97. Gordon P.M., Dias S., Williams D.A. Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis. Leukemia 2014, 28(11):2257-2260.
98. Brizuela L., et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol. Oncol. 2014, 8(7):1181-1195.
99. Perez-Gracia J.L., et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br. J. Cancer 2009, 101(11):1876-1883.
100. Huang D., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010, 70(3):1063-1071.
101. Porta C., et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010, 77(9):809-815.
102. Mitsunaga S., et al. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 2013, 108(10):2063-2069.
103. Seruga B., et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 2008, 8(11):887-899.
104. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22(5):347-352.
105. Matsusaka T., et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. 1993, 90(21):10193-10197.
106. Perkins N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 2012, 12(2):121-132.
107. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21(1):11-19.
108. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7(1):41-51.
109. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
110. Li F., Zhao C., Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int. J. Cancer 2014, 134(6):1257-1269.
111. Konermann S., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015, 517(7536):583-588.
112. Shalem O., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014, 343(6166):84-87.
113. Pemovska T., et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013, 3(12):1416-1429.
114. Crystal A.S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014, 346(6216):1480-1486.